Resources

Informative Resources

Take a look at the latest on Palatin across our media publications, posters, and presentations.

Protective Effects of Two Melanocortin Agonists Delivered by Intravitreal Injection in Mouse Models of Retinopathy

2021-September

Melanocortin agonists have demonstrated anti-inflammatory effects in various experimental models of inflammatory disease. PL8331 and PL9654 are melanocortin 1 receptor agonists being evaluated preclinically for the treatment of various ocular diseases.

Investor’s Day Presentation

2021-May

Melanocortin Agonists for Ocular Diseases

Protective Effects of 2 Melanocortin Agonists Delivered by Intravitreal Injection in Mouse Models of Retinopathy

2021-May

Melanocortins have a wide range of activities, including inhibition of leukocyte activation, inhibition of inflammation, and protection of tissues1-3 The melanocortin system plays a key role in promoting resolution of the inflammatory process

Efficacy and Safety of the Melanocortin Agonist PL9643 in a Phase 2 Study of Subjects With Dry Eye Disease

2021-May

This is a multifactorial inflammatory disease affecting multiple areas in the eye. Existing therapies are often inadequate due to poor efficacy, adverse effects, or poor tolerability.

Bremelanotide Provides Meaningful Treatment Benefits for Premenopausal Women With Hypoactive Sexual Desire Disorder

2019-October

Bremelanotide, a melanocortin receptor agonist and an analog of the endogenous neuropeptide α-melanocortin stimulating hormone, has been approved in the US for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. The RECONNECT studies demonstrated that subcutaneous self-administration of bremelanotide significantly improved sexual desire and decreased personal distress in premenopausal women with HSDD.

Scroll to Top